Ranbaxy to extend Daiichi Sankyo products to Italy

Ranbaxy Italia S.p.A (Ranbaxy) and Daiichi Sankyo, Italia S.p.A (Daiichi Sankyo), today announced a partnership to leverage .Ranbaxy's distribution strengths and extensive relationships with Pharmacists across Italy, for the distribution of Daiichi Sankyo products. To start with, Ranbaxy will exclusively distribute two of Daiichi Sankyo's long established brands - CONGESCOR and LOPRESOR - to all pharmacies, in the country. These drugs are used extensively by Doctors in Italy for the treatment of Congestive Heart Failure and Hypertension. As per IMS Health, the total annual retail sales of CONGESCOR and LOPRESOR are around Euro 20 Mn. The partnership in Italy provides further impetus to the Hybrid Business Model between the two companies by comprehensively addressing Doctors and Pharmacists in improving the accessibility of drugs, for patients.



Commenting on the development Neeraj Sharma, Managing Director, Ranbaxy TtaJia S.p.A, said, "Ranbaxy will use its extensive sales force network to ensure adequate retail presence for CONGESCOR and LOPRESOR and provide Daiichi Sankyo with direct access to the Pharmacists, who are important stakeholders, in the pharmaceutical value chain. The arrangement will ensure the wide availability of the drugs and improve their accessibility for patients." Daiichi Sankyo, Italia, through its dedicated team of Medical Representatives, will continue to take care of the Physicians, mainly Cardiologists and Internists, promoting the two products. Welcoming the arrangement, Antonino Rcale, Managing Director, Daiichi Sankyo, Italia, S.p.A said, "The partnership extends our product reach and brings together the strength and the market equity of the Daiichi Sankyo brands, combining these aspects, with the strong pharmacy sales and distribution network of Ranbaxy, for mutual advantage."